Base by Base

Herger M et al., Cell Genomics - Herger et al. present a pooled prime editing platform in haploid human cells that installs and assays thousands of short variants in their endogenous context. Using surrogate targets, co-selection and stringent pegRNA filtering, negative and positive selection screens identify loss-of-function variants in SMARCB1 and MLH1, including non-coding ClinVar variants that alter splicing. Key terms: prime editing, variant functional screening, SMARCB1, MLH1, HAP1 cells.

Study Highlights:
The authors develop a lentiviral pooled prime editing (PE) platform in HAP1 cells incorporating surrogate target (ST) sequences and co-selection to enrich edited cells. They optimize pegRNA scaffold design and show that ST editing rates are a useful proxy to filter active pegRNAs from inactive ones. Negative (essentiality) and positive (6-thioguanine) selection screens reveal novel loss-of-function variants in SMARCB1 and MLH1 across coding and non-coding regions. Stringent pegRNA activity filtering and orthogonal validation are necessary to reduce false positives and negatives.

Conclusion:
Pooled prime editing with surrogate targets and co-selection can scalably reveal functional effects of coding and non-coding human variants in their native genomic context, but accurate scoring depends on pegRNA activity and validation; improvements in pegRNA design and prime editors should expand genome-wide applicability.

QC:
This episode was checked against the original article PDF and publication metadata for the episode release published on 2025-05-16.

QC Scope:
- article metadata and core scientific claims from the narration
- excludes analogies, intro/outro, and music

QC Summary:
- factual score: 10/10
- metadata score: 10/10
- supported core claims: 8
- claims flagged for review: 0
- metadata checks passed: 4
- metadata issues found: 0

Metadata Audited:
- article_doi
- article_title
- article_journal
- license

Factual Items Audited:
- Pooled prime editing platform enables scalable installation of variants in haploid human cells (HAP1).
- Surrogate targets (ST) and co-selection improve data quality by informing pegRNA activity and enriching edited cells.
- Negative selection identifies LoF variants in SMARCB1; positive selection using 6TG identifies LoF variants in MLH1.
- ST editing rates correlate with endogenous editing; ST editing is a proxy for ET editing.
- Non-coding ClinVar variants in MLH1 can be functionally scored; 362 of 874 non-coding ClinVar variants were assigned function scores.
- Pathogenic ClinVar variants in the MLH1 region show LoF scores; 54% called LoF; benign 2.4%.

QC result: Pass.

Mousa A et al., Nature Communications - Pooled analysis of seven therapeutic efficacy trials (1639 participants, 12 African sites) quantifies how dhps resistance genotypes shorten the duration of protection from sulfadoxine-pyrimethamine (SP) and maps predicted chemoprevention impact across Africa. Key terms: sulfadoxine-pyrimethamine, dhps mutations, chemoprevention, malaria, genomic surveillance.

Study Highlights:
The authors pooled individual-level data from seven trials (1639 participants) and used a Bayesian multi-strain Weibull survival model to estimate genotype-specific durations of SP protection while accounting for site-level transmission. Mean protection against sulfadoxine-susceptible dhps AKA parasites was longest (≈55.7 days), intermediate for dhps GKA (≈33.9 days), and substantially shorter for dhps GEA (≈10.7 days) and dhps GEG (≈11.7 days). SP combined with amodiaquine (SPAQ) showed markedly longer protection against GEA in the available data (≈42.5 days). The study produced maps and a web tool to predict local SP protective efficacy using genomic surveillance inputs.

Conclusion:
dhps resistance mutations substantially reduce the duration of SP post-treatment protection; integrating genotype surveillance into policy can guide where SP-based chemoprevention is likely to remain effective and where alternatives such as SPAQ should be considered.

QC:
This episode was checked against the original article PDF and publication metadata for the episode release published on 2025-05-16.

QC Scope:
- article metadata and core scientific claims from the narration
- excludes analogies, intro/outro, and music

QC Summary:
- factual score: 10/10
- metadata score: 10/10
- supported core claims: 6
- claims flagged for review: 0
- metadata checks passed: 4
- metadata issues found: 0

Metadata Audited:
- article_doi
- article_title
- article_journal
- license

Factual Items Audited:
- SP protection duration varies by dhps genotype; longest against sulfadoxine-susceptible AKA parasites (~55.7–56 days) and shorter for GKA (~33.9 days), GEA (~10.7 days), and GEG (~
- SPAQ (SP + amodiaquine) provides markedly longer protection against GEA than SP alone, with ~42.5 days versus ~10.7 days for SP alone.
- Validation with IPTi trials showed model predictions closely matched observed reinfection rates, supporting generalizability of genotype-specific protection estimates.
- A web-based tool was developed to predict SP protective efficacy based on local dhps genotype frequencies, enabling policy tailoring.
- Across sub-Saharan Africa, 30-day protective efficacy against infection varies from about 59% to 92%, with a mean of approximately 4.7 clinical malaria cases averted per 100 childr
- Policy implications: strategies should be tailored to local resistance patterns, using molecular surveillance to guide where SP is effective and where alternatives (e.g., SPAQ) sho

QC result: Pass.

Martin‑Geary AC et al et al., Genome Medicine - A systematic framework to prioritise promoter and UTR variants in 8040 undiagnosed trios from the Genomics England 100,000 Genomes Project, yielding ten likely diagnoses and a validated annotation pipeline for clinical use. Key terms: promoters, untranslated regions, de novo variants, rare disease, Genomics England.

Study Highlights:
The authors applied a region‑specific annotation and strict filtering pipeline to de novo variants in 8040 undiagnosed trios, focusing on proximal promoters and UTRs of dominant disease genes. Eleven candidate de novo variants (twelve total) were prioritised; ten lie in genes that match the proband phenotype and six represent newly identified diagnoses. Validation included RNA‑seq and DNA methylation where available, and pipeline benchmarking against ClinVar showed high specificity. Burden testing in 7862 probands versus matched controls did not show a significant collective enrichment of prioritised promoter/UTR variants.

Conclusion:
Screening proximal promoters and UTRs can uncover additional rare disease diagnoses and the authors provide a high‑specificity framework for clinical pipelines, but routinely including these regions is unlikely to dramatically increase overall diagnostic yield.

QC:
This episode was checked against the original article PDF and publication metadata for the episode release published on 2025-05-14.

QC Scope:
- article metadata and core scientific claims from the narration
- excludes analogies, intro/outro, and music

QC Summary:
- factual score: 10/10
- metadata score: 10/10
- supported core claims: 7
- claims flagged for review: 0
- metadata checks passed: 4
- metadata issues found: 0

Metadata Audited:
- article_doi
- article_title
- article_journal
- license

Factual Items Audited:
- Framework to identify proximal promoter and UTR variants in known dominant disease genes was developed
- DNVs in 8040 undiagnosed individuals were analyzed; 1311 DNVs in 1118 probands
- Ten likely disease-causing promoter/UTR DNVs in ten individuals; nine prioritized and one SETD5 variant
- Four new diagnoses including SLC2A1, NIPBL, ZBTB18, SETD5; methylation episignature supporting SETD5
- Burden testing did not show significant enrichment of promoter/UTR variants in cases vs controls
- ClinVar analysis shows high specificity; pathogenic variants prioritized ~53.7%; benign ~0.71%

QC result: Pass.

Dardas Z et al., The American Journal of Human Genetics - This episode reviews Dardas et al. (2025), which identifies bi-allelic UGGT1 variants in 15 affected individuals as the cause of a distinct congenital disorder of glycosylation (UGGT1-CDG), describes the clinical spectrum, and dissects diverse molecular mechanisms that impair UGGT1 function. Key terms: UGGT1, congenital disorder of glycosylation, neurodevelopmental disorder, glucosyltransferase, ER quality control.

Study Highlights:
Fifteen individuals from ten unrelated families were shown to harbor bi-allelic UGGT1 variants associated with a variable multisystem phenotype dominated by global developmental delay, intellectual disability, seizures, dysmorphic facial features, and frequent microcephaly. Functional studies demonstrated that pathogenic variants impair UGGT1 glucosyltransferase catalytic activity, disrupt mRNA splicing, or abrogate ER retention causing extracellular secretion. Genotype–phenotype correlations indicate that bi-allelic loss-of-function alleles associate with greater severity, including infant death, whereas hypomorphic alleles permit survival with neurodevelopmental disability. Standard transferrin testing was often normal, highlighting the need for genetic testing when clinical suspicion for a CDG is high.

Conclusion:
Bi-allelic UGGT1 variants define UGGT1-CDG, a clinically variable N-linked glycosylation disorder in which distinct molecular mechanisms—loss of catalytic activity, splicing disruption, or loss of ER retention—compromise ER quality control and underlie neurologic and multisystem disease; genetic testing is recommended when CDG is suspected as transferrin assays may be normal.

QC:
This episode was checked against the original article PDF and publication metadata for the episode release published on 2025-05-13.

QC Scope:
- article metadata and core scientific claims from the narration
- excludes analogies, intro/outro, and music

QC Summary:
- factual score: 10/10
- metadata score: 10/10
- supported core claims: 5
- claims flagged for review: 0
- metadata checks passed: 4
- metadata issues found: 0

Metadata Audited:
- article_doi
- article_title
- article_journal
- license

Factual Items Audited:
- UGGT1-CDG is caused by bi-allelic UGGT1 variants (15 individuals from 10 families).
- Pathogenic UGGT1 variants impair glucosyltransferase activity, disrupt splicing, or inhibit ER retention.
- Transferrin testing may be normal; genetic testing is essential for diagnosis.
- Arg1546* UGGT1 variant represents an Arab founder variant with a shared haplotype.
- Survival beyond infancy is possible with hypomorphic (missense) UGGT1 variants; null alleles associated with more severe outcomes including perinatal death.
- Total UGGT1-CDG cases described

QC result: Pass.

Juen Z et al., Cell - This episode examines a cryo-EM study that resolves the human sweet taste receptor (TAS1R2+TAS1R3) bound to two artificial sweeteners, revealing how a single receptor recognizes diverse sweet compounds and couples to G proteins. Key terms: sweet taste receptor, TAS1R2, TAS1R3, cryo-EM, sucralose.

Study Highlights:
Single-particle cryo-EM determined the structure of the human TAS1R2+TAS1R3 heterodimer bound to sucralose and aspartame at multi-angstrom resolution. The TAS1R2 subunit contains a conserved Venus flytrap (VFT) binding pocket that accommodates both sucralose and aspartame, while TAS1R3 remains in an open conformation. Site-directed mutagenesis of VFT residues (e.g., Y103, D142, S165, Y215, D278) altered ligand responses, supporting the mapped pocket. 3D variability analysis shows coordinated conformational changes between subunits and identifies elements linking ligand binding to the transmembrane and G protein-coupling regions.

Conclusion:
The cryo-EM structures define a common TAS1R2 binding pocket for high-potency sweeteners and reveal structural features linking agonist binding to G protein coupling, providing a foundation for structure-guided modulation of sweet taste.

QC:
This episode was checked against the original article PDF and publication metadata for the episode release published on 2025-05-13.

QC Scope:
- article metadata and core scientific claims from the narration
- excludes analogies, intro/outro, and music

QC Summary:
- factual score: 10/10
- metadata score: 10/10
- supported core claims: 7
- claims flagged for review: 0
- metadata checks passed: 4
- metadata issues found: 0

Metadata Audited:
- article_doi
- article_title
- article_journal
- license

Factual Items Audited:
- The human sweet receptor TAS1R2+TAS1R3 forms an obligatory heterodimer mediating sweet detection.
- There is a common binding pocket in TAS1R2 that binds both sucralose and aspartame.
- TAS1R2 is the ligand-binding and G protein-coupling subunit; TAS1R3 anchors and maintains open conformation.
- Key pocket residues Y103, D142, S165, Y215, D278 mediate ligand recognition; mutations disrupt function.
- G protein coupling involves TAS1R2 residues Y756 and F827; mutations disrupt coupling.
- TAS1R3 contributes to VFT dynamics and receptor activation; mutations in TAS1R3 affect function.

QC result: Pass.

Arruda AL et al., Cell Genomics - A commentary calling for generation of tissue-specific molecular data across diverse ancestries to improve fine-mapping, causal inference, and equitable translation of GWAS findings beyond Eurocentric and blood-focused resources. Key terms: genomic equity, multi-ancestry, molecular QTL, tissue-specific, GWAS.

Study Highlights:
The authors document pervasive Eurocentric bias across GWAS and molecular QTL resources and note that most available molecular data with genetics are derived from blood. They argue that tissue-specific regulatory variation and ancestry differences in linkage disequilibrium require primary-tissue multi-ancestry molecular datasets to resolve noncoding GWAS signals. GTEx and other initiatives contribute valuable data but have limited non-European sample sizes and incomplete ancestry metadata, constraining colocalization and causal inference. The commentary calls for targeted funding, infrastructure, community engagement, and global collaboration to generate diverse tissue molecular data.

Conclusion:
To achieve equitable and translatable genomics, the field must prioritize generation of tissue-specific, multi-ancestry molecular datasets, improve ancestry metadata, and invest in methods and partnerships that enable inclusive fine-mapping and functional interpretation.

QC:
This episode was checked against the original article PDF and publication metadata for the episode release published on 2025-04-25.

QC Scope:
- article metadata and core scientific claims from the narration
- excludes analogies, intro/outro, and music

QC Summary:
- factual score: 10/10
- metadata score: 10/10
- supported core claims: 6
- claims flagged for review: 0
- metadata checks passed: 4
- metadata issues found: 0

Metadata Audited:
- article_doi
- article_title
- article_journal
- license

Factual Items Audited:
- GWAS are biased toward European-ancestry populations; diversification broadens discovery.
- Multiancestry data improves fine-mapping by enabling smaller LD blocks and better localization of causal variants.
- Lack of ancestry metadata and tissue-specific molecular data is a bottleneck; GTEx data show limited non-European samples and power issues when stratified by tissue.
- Colocalization and Mendelian randomization link GWAS signals to molecular traits to infer causal mechanisms.
- Ugandan eGFR study identified an African-specific intergenic variant at the GATM locus; this variant is monomorphic in European ancestry and rare in East Asian ancestry, illustrati
- Longitudinal multi-omics data across tissues is a long-term goal to enable dynamic understanding of health and disease across diverse populations.

QC result: Pass.

Zeberg H et al., Cell - A review of genetic differences among modern humans, Neandertals, and Denisovans, their functional consequences, and how introgression and lineage-specific changes shaped traits from immunity to neurodevelopment. Key terms: Neandertal introgression, Denisovan introgression, modern human evolution, adaptive introgression, archaic DNA.

Study Highlights:
Modern human ancestors diverged from Neandertals and Denisovans about 600,000 years ago and later experienced intermittent gene flow that left archaic DNA fragments in present-day genomes. The review surveys functional impacts of introgressed and modern-human-specific variants on metabolism, immunity, reproduction, sensation, and neurogenesis, citing examples such as SLC16A11, EPAS1, Toll-like receptors, the chromosome 3 COVID-19 risk haplotype, and modern substitutions affecting purine biosynthesis and mitosis in neural progenitors. It argues that modern human uniqueness is best viewed as a combinatorial set of derived variants rather than single universally fixed changes and highlights expanding, diverse biobanks and experimental systems as key to future functional insight.

Conclusion:
Modern human distinctiveness arises from a combination of lineage-specific substitutions and introgressed alleles whose functional effects vary by locus and population; studying archaic contributions and modern-specific changes via diverse genomic cohorts and functional models will clarify their physiological and medical relevance.

QC:
This episode was checked against the original article PDF and publication metadata for the episode release published on 2025-04-25.

QC Scope:
- article metadata and core scientific claims from the narration
- excludes analogies, intro/outro, and music

QC Summary:
- factual score: 10/10
- metadata score: 10/10
- supported core claims: 8
- claims flagged for review: 0
- metadata checks passed: 4
- metadata issues found: 0

Metadata Audited:
- article_doi
- article_title
- article_journal
- license

Factual Items Audited:
- Modern humans outside Africa have Neanderthal DNA comprising about 2% of their genome.
- Denisovan ancestry contributes >5% of the genome in some Oceanian populations; overall Denisovan ancestry is around 0.2% in many populations.
- Archaic DNA segments are typically ~50 kb in length today, with some segments as small as ~12 kb representing older shared ancestry.
- A Neanderthal variant in SCN9A (sodium channel) increases pain sensitivity; around 0.4% of UK population carries the Neanderthal version.
- A Neanderthal haplotype on chromosome 3 increases risk of severe COVID-19 (ventilation/dying) but reduces HIV risk via CCR5 downregulation (~25% reduced infection risk).
- Denisovan EPAS1 haplotype contributes to high-altitude adaptation in Tibetans (often >80% carry the Denisovan segment).

QC result: Pass.

Horn R et al., European Journal of Human Genetics - Workshop report assessing the practical benefits and limits of national genomic programmes across societal, economic, clinical, scientific and population levels, and proposing criteria to ensure public benefit, equity and robust evaluation. Key terms: genomic programmes, public trust, economic evaluation, equity, newborn screening.

Study Highlights:
An international workshop produced a taxonomy of benefits of large-scale genomic programmes at societal, economic, clinical, scientific and population levels. Participants highlighted gaps in evidence—especially economic evaluations—and the limited predictive value of genomics for many common diseases. Trust, governance, equity and transparent communication emerged as essential conditions for public benefit. The report calls for targeted, evidence-driven rollouts and multidisciplinary evaluation frameworks before population-wide implementation.

Conclusion:
Large-scale genomic programmes offer potential benefits across multiple levels but current evidence is incomplete, especially on economic value and population impact. To justify public investment and maintain trust, programmes must avoid overpromising, prioritise rigorous upstream and downstream evaluation, address equity and consent, and proceed with targeted, evidence-based implementation supported by transparent governance.

QC:
This episode was checked against the original article PDF and publication metadata for the episode release published on 2025-04-25.

QC Scope:
- article metadata and core scientific claims from the narration
- excludes analogies, intro/outro, and music

QC Summary:
- factual score: 10/10
- metadata score: 10/10
- supported core claims: 7
- claims flagged for review: 0
- metadata checks passed: 4
- metadata issues found: 0

Metadata Audited:
- article_doi
- article_title
- article_journal
- license

Factual Items Audited:
- Public trust is essential for large-scale genomic programmes; distrust reveals governance gaps, especially regarding public-private data partnerships.
- Economic value of large-scale sequencing programmes is not yet proven; there is a severe lack of population-level economic evidence, with Denmark cited as a failure to establish an
- Polygenic risk scores have limited predictive power for most common diseases; environment and epigenetic factors explain the majority of risk; risk of overdiagnosis or false reassu
- Multidisciplinary advisory boards (e.g., molecular tumor boards) and ESMO-style frameworks help interpret genomic data and prevent over-interpretation or inappropriate intervention
- Population-level implementation faces equity challenges; data bias toward wealthy, European-descent populations risks widening health disparities; targeted, equity-focused rollout
- The Genomics England Generation Study (100,000 newborns; screening for >200 conditions) is a key example, illustrating potential societal benefits but raising consent and feasibili

QC result: Pass.

Nature - A telomere‑to‑telomere, multigenerational study that uses five sequencing technologies to assemble and phase near‑complete diploid genomes from a 28‑member family (CEPH 1463) to measure de novo mutation rates across the genome. Key terms: de novo mutation, long-read sequencing, tandem repeats, centromeres, Y chromosome.

Study Highlights:
The authors generated phased, near‑T2T assemblies for members of a four‑generation pedigree and traced inheritance to estimate 98–206 de novo mutations per transmission, including single‑nucleotide, indel, tandem‑repeat and structural variants. Short tandem repeats and larger VNTRs, centromeres and Yq12 satellite DNA are far more mutable than euchromatin, with 32 recurrently mutated TR loci and 288 assembled centromeres revealing integer HOR changes. There is a strong paternal bias (≈75–81%) for germline DNMs and a paternal age effect for germline SNVs, while 16% of autosomal SNVs are postzygotic and show no paternal bias. A high‑resolution recombination map (~3.4 kb breakpoint resolution) was produced and no correlation was found between meiotic crossovers and de novo structural variants.

Conclusion:
Multiplatform long‑read assemblies across four generations provide a near‑complete pedigree truth set that revises genome‑wide and region‑specific de novo mutation rates, highlights repeat‑driven mutability, and offers a benchmark for future mutation‑rate and assembly studies.

QC:
This episode was checked against the original article PDF and publication metadata for the episode release published on 2025-04-25.

QC Scope:
- article metadata and core scientific claims from the narration
- excludes analogies, intro/outro, and music

QC Summary:
- factual score: 10/10
- metadata score: 10/10
- supported core claims: 8
- claims flagged for review: 0
- metadata checks passed: 4
- metadata issues found: 0

Metadata Audited:
- article_doi
- article_title
- article_journal
- license

Factual Items Audited:
- De novo mutation rate per transmission is 98–206 with average 152, roughly doubling prior estimates.
- Repeat-rich regions (centromeres, SDs, Yq12 satellites) have elevated mutation rates; Yq12 satellites are ~30x more mutable than euchromatin.
- Paternal bias in germline DNMs is strong (75–81%), and paternal age increases DNMs by ~1.55 per year.
- Postzygotic DNMs constitute about 16% of de novo SNVs and show no paternal bias.
- Centromeres show de novo SVs and SNVs; reported 18 de novo SVs in centromeres and 16 centromeric SNVs with elevated rate.
- Y chromosome DNMs are high due to Yq12 repeats; SNV rate across MSY is 1.99e-7 per bp per generation.

QC result: Pass.

Trasviña-Arenas CH et al., Nature Communications - This episode explores a 2025 study that reports the first human MUTYH structure bound to a transition state analog and functional profiling of cancer-associated variants near its [4Fe-4S] cluster. The authors map an evolutionarily conserved hydrogen-bond network linking the metal cluster to the catalytic Asp236 and show how specific variants disrupt catalysis. Two variants (R241Q, N238S) retain metal binding and DNA affinity yet lose glycosylase activity, revealing an allosteric regulatory role for the cofactor. Molecular dynamics and a bacterial homolog structure support a model in which the cluster positions and modulates the catalytic residue to enable adenine excision. Key terms: MUTYH, 4Fe-4S cluster, base excision repair, allosteric network, cancer-associated variants.

Study Highlights:
Researchers solved a 1.9 Å human MUTYH–transition state analog crystal structure that uncovers a hydrogen-bond bridge from the [4Fe-4S] cluster to the active site. Functional profiling of 12 cancer-associated variants near the cluster shows most lose cofactors and activity, while R241Q and N238S uniquely retain metals and DNA binding but are inactive. A corresponding bacterial R149Q structure and molecular dynamics reveal alternate cluster conformations and altered dynamics that disrupt communication to catalytic Asp236. Together the data support an allosteric network that positions and affects the protonation state of Asp236 to enable base excision.

Conclusion:
The [4Fe-4S] cluster in MUTYH is an active allosteric element connected to the catalytic pocket via a conserved Cys290–Arg241–Asn238–Asp236 hydrogen-bond network; disruption of this bridge by cancer-associated variants can disable DNA repair even when metal binding and DNA affinity are retained, highlighting a mechanism for MUTYH-associated mutagenesis and a potential regulatory or therapeutic target.

QC:
This episode was checked against the original article PDF and publication metadata for the episode release published on 2025-04-19.

QC Scope:
- article metadata and core scientific claims from the narration
- excludes analogies, intro/outro, and music

QC Summary:
- factual score: 10/10
- metadata score: 10/10
- supported core claims: 8
- claims flagged for review: 0
- metadata checks passed: 4
- metadata issues found: 0

Metadata Audited:
- article_doi
- article_title
- article_journal
- license

Factual Items Audited:
- There is a 20 Å hydrogen-bond network bridging the [4Fe-4S] cluster to the active site, connecting Cys290–Arg241–Asn238–Asp236 to position and modulate Asp236 for base excision.
- Crystal structure of human MUTYH with DNA bound (MUTYH-TSAC) demonstrates the bridge between the [4Fe-4S] cluster and active site, supporting allosteric cross-talk.
- R241Q and N238S cancer-associated variants retain metal cofactor and DNA binding yet are catalytically inactive, illustrating allosteric disruption without global unfolding.
- Most cancer-associated variants near the [4Fe-4S] cluster disrupt metal cofactors and cause loss of activity; exceptions (R241Q/N238S) retain metal/DNA binding but are inactive.
- The allosteric network is evolutionarily conserved across MUTYH and related HhH BER glycosylases (e.g., MIG, EndoIII).
- Under oxidative stress, oxidation state changes of the [4Fe-4S] cluster act as an environmental sensor that down-regulates MUTYH to prevent catastrophic genome fragmentation.

QC result: Pass.